Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways

CONTEXT: Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease, can develop into metabolic associated fatty liver disease (MAFLD). Gypenosides (GP), the main phytochemical component of Gynostemma pentaphylla (Thunb.) Makino (Cucurbitaceae), have been applied for treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Shuhua, Wang, Kungen, Zhi, Yihui, Dong, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553138/
https://www.ncbi.nlm.nih.gov/pubmed/36205541
http://dx.doi.org/10.1080/13880209.2022.2126503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553138/
https://www.ncbi.nlm.nih.gov/pubmed/36205541
http://dx.doi.org/10.1080/13880209.2022.2126503

Ejemplares similares